These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 38132096)

  • 1. New Perspectives in Radiological and Radiopharmaceutical Hybrid Imaging in Progressive Supranuclear Palsy: A Systematic Review.
    Strobel J; Müller HP; Ludolph AC; Beer AJ; Sollmann N; Kassubek J
    Cells; 2023 Dec; 12(24):. PubMed ID: 38132096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebral Tau Deposition in Comorbid Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis: An [18F]-Flortaucipir and 7T MRI Study.
    Cheong I; Du Y; Smith G; Hua J; Li X; Pantelyat A
    Neurodegener Dis; 2023; 23(3-4):35-42. PubMed ID: 38527450
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Nicastro N; Rodriguez PV; Malpetti M; Bevan-Jones WR; Simon Jones P; Passamonti L; Aigbirhio FI; O'Brien JT; Rowe JB
    J Neurol; 2020 Feb; 267(2):341-349. PubMed ID: 31641878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroinflammation predicts disease progression in progressive supranuclear palsy.
    Malpetti M; Passamonti L; Jones PS; Street D; Rittman T; Fryer TD; Hong YT; Vàsquez Rodriguez P; Bevan-Jones WR; Aigbirhio FI; O'Brien JT; Rowe JB
    J Neurol Neurosurg Psychiatry; 2021 Jul; 92(7):769-775. PubMed ID: 33731439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy.
    Whitwell JL; Tosakulwong N; Schwarz CG; Botha H; Senjem ML; Spychalla AJ; Ahlskog JE; Knopman DS; Petersen RC; Jack CR; Lowe VJ; Josephs KA
    Mov Disord; 2019 Jan; 34(1):105-113. PubMed ID: 30468693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study.
    Holland N; Malpetti M; Rittman T; Mak EE; Passamonti L; Kaalund SS; Hezemans FH; Jones PS; Savulich G; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2022 Mar; 145(1):340-348. PubMed ID: 34398211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcortical
    Cho H; Choi JY; Hwang MS; Lee SH; Ryu YH; Lee MS; Lyoo CH
    Mov Disord; 2017 Jan; 32(1):134-140. PubMed ID: 27813160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants.
    Orlandi F; Carlos AF; Ali F; Clark HM; Duffy JR; Utianski RL; Botha H; Machulda MM; Stephens YC; Schwarz CG; Senjem ML; Jack CR; Agosta F; Filippi M; Dickson DW; Josephs KA; Whitwell JL
    Brain Commun; 2024; 6(2):fcae113. PubMed ID: 38660629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
    Whitwell JL; Höglinger GU; Antonini A; Bordelon Y; Boxer AL; Colosimo C; van Eimeren T; Golbe LI; Kassubek J; Kurz C; Litvan I; Pantelyat A; Rabinovici G; Respondek G; Rominger A; Rowe JB; Stamelou M; Josephs KA;
    Mov Disord; 2017 Jul; 32(7):955-971. PubMed ID: 28500751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive supranuclear palsy.
    Giagkou N; Höglinger GU; Stamelou M
    Int Rev Neurobiol; 2019; 149():49-86. PubMed ID: 31779824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome.
    Williams DR; Holton JL; Strand C; Pittman A; de Silva R; Lees AJ; Revesz T
    Brain; 2007 Jun; 130(Pt 6):1566-76. PubMed ID: 17525140
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Liu FT; Lu JY; Li XY; Liang XN; Jiao FY; Ge JJ; Wu P; Li G; Shen B; Wu B; Sun YM; Zhu YH; Luo JF; Yen TC; Wu JJ; Zuo CT; Wang J;
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1395-1405. PubMed ID: 36627498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy.
    Brendel M; Barthel H; van Eimeren T; Marek K; Beyer L; Song M; Palleis C; Gehmeyr M; Fietzek U; Respondek G; Sauerbeck J; Nitschmann A; Zach C; Hammes J; Barbe MT; Onur O; Jessen F; Saur D; Schroeter ML; Rumpf JJ; Rullmann M; Schildan A; Patt M; Neumaier B; Barret O; Madonia J; Russell DS; Stephens A; Roeber S; Herms J; Bötzel K; Classen J; Bartenstein P; Villemagne V; Levin J; Höglinger GU; Drzezga A; Seibyl J; Sabri O
    JAMA Neurol; 2020 Nov; 77(11):1408-1419. PubMed ID: 33165511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interplay of tau and functional network connectivity in progressive supranuclear palsy: a [
    Aghakhanyan G; Rullmann M; Rumpf J; Schroeter ML; Scherlach C; Patt M; Brendel M; Koglin N; Stephens AW; Classen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):103-114. PubMed ID: 36048259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants.
    Whitwell JL; Tosakulwong N; Botha H; Ali F; Clark HM; Duffy JR; Utianski RL; Stevens CA; Weigand SD; Schwarz CG; Senjem ML; Jack CR; Lowe VJ; Ahlskog JE; Dickson DW; Josephs KA
    Neuroimage Clin; 2020; 25():102152. PubMed ID: 31935638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synaptic Loss in Primary Tauopathies Revealed by [
    Holland N; Jones PS; Savulich G; Wiggins JK; Hong YT; Fryer TD; Manavaki R; Sephton SM; Boros I; Malpetti M; Hezemans FH; Aigbirhio FI; Coles JP; O'Brien J; Rowe JB
    Mov Disord; 2020 Oct; 35(10):1834-1842. PubMed ID: 32652635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy.
    Malpetti M; Passamonti L; Rittman T; Jones PS; Vázquez Rodríguez P; Bevan-Jones WR; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Ann Neurol; 2020 Dec; 88(6):1194-1204. PubMed ID: 32951237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncovering distinct progression patterns of tau deposition in progressive supranuclear palsy using [
    Hong J; Lu J; Liu F; Wang M; Li X; Clement C; Lopes L; Brendel M; Rominger A; Yen TC; Guan Y; Tian M; Wang J; Zuo C; Shi K;
    EBioMedicine; 2023 Nov; 97():104835. PubMed ID: 37839135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodal neuroimaging relationships in progressive supranuclear palsy.
    Sintini I; Schwarz CG; Senjem ML; Reid RI; Botha H; Ali F; Ahlskog JE; Jack CR; Lowe VJ; Josephs KA; Whitwell JL
    Parkinsonism Relat Disord; 2019 Sep; 66():56-61. PubMed ID: 31279635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau imaging with [
    Ishiki A; Harada R; Okamura N; Tomita N; Rowe CC; Villemagne VL; Yanai K; Kudo Y; Arai H; Furumoto S; Tashiro M; Furukawa K
    Eur J Neurol; 2017 Jan; 24(1):130-136. PubMed ID: 27797445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.